Reviewer #1 (Remarks to the Author):
1.
It is interesting that the animals were PFA fixed first and then the luciferase substrate was added. Is it because of high sensitivity of this NanoLuc?
2.
What changes in the apoB containing lipoproteins when their size become smaller and render them more atherogenic? Any in vitro or in vivo evidence?
Reviewer #3 (Remarks to the Author):
This manuscript describes experiments to develop and validate the LipoGlo reporter for apoB containing lipoproteins in zebrafish. The authors have tagged the zebrafish homolog of apoB with a luciferase tag which allows the tracking of its lipoproteins around the transparent fish larvae. In addition, the larvae can be ground up and the lipoproteins analyzed by electrophoretic techniques to determine general distributions between CM, VLDL, IDL and LDL. The authors used the system to identify potentially new sites of apoB-LP association within the larval body and, as a proof of concept, identified a gene that likely affects apoB-LP metabolism in fish. Overall, this is an interesting system. The resolution of the system, both in terms of the gel electrophoresis size analysis and the whole body localization studies, is perhaps a bit disappointing. I was hoping that it might be possible to see associations that are more related to atherosclerosis development like accumulation of apoBLPs in the vasculature, for example. However, it clearly has potential uses in screening for genes and drug treatments that affect apoB-LP metabolism. However, there were some deficiencies in the characterization of the system and inconsistencies in the data that reduced enthusiasm for this work in its current state. My specific comments are outlined below.
1)
The abbreviation ABCLs seems a bit clunky for apoB containing lipoproteins. The authors should consider using a more intuitive abbreviation like apoB-LPs or something similar. It is only a little longer, but much clearer.
2)
The conclusion that the LipoGlo signal does not disrupt normal production, secretion and turnover of lipoproteins appears based on the observation that the homozygous fish are healthy, fertile with no abnormal or morphological phenotypes. This seems like light evidence. One would expect to see some sort of size pattern analysis between WT and homozygous fish to show that they are similar. Also, a demonstration that the modified LPs can interact with the LDL receptor to a similar extent as WT would also be in order. I realize that it is difficult to get enough material for these types of validations from fish. But these days it should be relatively straightforward to produce this same tag in a mouse system where the consequences of the tag attachment can be very easily studied and compared to non-labeled (i.e. LDL-R binding, size pattern, etc). As it stands, I am not convinced by the data presented that the tag is completely benign for apoB function.
3)
The method uses crude larval homogenates. Presumably, this captures those lipoproteins in plasma. However, with cellular disruption that is also undoubtedly occurring, how can the authors distinguish between mature plasma particles and those intracellular particles still undergoing synthesis?
4)
The size analyses of the homogenates seem problematic. The authors used a Di-I labeled (presumably human) LDL as a standard in the analysis. However, the migration of this standard in Fig. 3a clearly falls between IDL and VLDL in the size profile laid out in Fig. 3b . For example, the standard runs just below the particles classified as "VLDL" in the apoC2 KO homogenates. The authors state that the Di-I stain reduces the mobility of the standard (data not shown). So why use this as a standard? It would seem much more rigorous to introduce this same tag into mouse apoB 100 (as suggested above) and use mouse plasma lipoproteins (identically tagged) as a proper and much more comprehensive reference.
5)
The subclass abundance plots do not make sense in Fig. 3F . Take the first panel, WT. The plot suggests that the levels of VLDL at day 3 are lower than they are at day 5. This is inconsistent with the gel image in panel C. Another example is apparent in the apoC2-/-plot. The graph suggests that VLDL levels in days 3 and 4 are on par with days 5 and 6. However, they are clearly reduced in day 5 and 6 in the gel image.
6)
Some figure references in the text are incorrect. Example, line 293.
Introduction to response:
We would like to thank the reviewers for their thorough evaluation of our manuscript entitled "LipoGlo: A sensitive and specific reporter of atherogenic lipoproteins". We are pleased that the reviewers appreciate the novelty and potential significance of this approach in studying the biology of ApoB-containing lipoproteins, especially as it relates to high-throughput genetic and small-molecule screening. The reviewers also highlighted several major concerns, and in response we have performed numerous additional experiments and significantly revised the manuscript as outlined below Three major concerns stood out in the review as particularly essential to the rigor of this manuscript. Firstly, reviewers expressed concerns that the NanoLuc tag may not remain physically attached to ApoB. To address this, we performed denaturing polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting and detected a prominent single band corresponding to the high molecular-weight ApoB-NanoLuc fusion protein, indicating that essentially all of the NanoLuc protein remains attached to ApoB. Secondly, reviewers expressed concern that NanoLuc may disrupt the lipoprotein profile. We add significant discussion of how existing experiments support that the lipoprotein profile remains unchanged, and performed additional experiments using lipophilic dyes to stain adult plasma and show that the profile in transgenic animals is indistinguishable from wild-type. Lastly, reviewers expressed concern that the lipoprotein localization may be altered as a result of the NanoLuc tag, as there is little evidence to corroborate the novel observation of lipoproteins associated with the myosepta and central nervous system. We addressed this concern using experiments suggested by reviewers, and have developed a new set of methods that uses DiI or DiI-labeled LDL as an orthogonal approach to track lipoproteins in vivo. This alternative approach corroborated our earlier conclusions, which we have further strengthened with additional citations from the literature.
Here we seek to establish a proof-of-principle that tagged lipoproteins serve as a powerful new strategy to advance our understanding of lipoprotein biology, particularly using the zebrafish system, and provide an example of how this can be achieved and validated. Publication of this manuscript in its current form can be used to guide the simultaneous translation of this approach to numerous additional model systems, including mouse.
The remaining concerns are addressed on a point-by-point basis below, and we have attached the significantly revised manuscript to be reconsidered for publication.
Response to specific concerns:
(Remarks to the Author): The authors develop a new method to track and image distribution of ApoB-containing lipoproteins based on a genetic fusion with the luciferase enzyme, NanoLuc. With this genetic reporter, they present assays for analyzing total amount of ApoB lipoproteins, particle types based on electrophoresis, and distribution in vivo based on imaging fixed zebrafish. They establish the approach can be applied to testing mutants and compounds. While NanoLuc has been fused to other proteins and used for imaging studies in vitro and in vivo, the described application is novel and applicable to relevant biologic questions. The presented in vivo images are convincing. Statistics are methods are appropriate to allow investigators to reproduce the imaging methods. Specific comments are listed below:
Reviewer #1 Point 1: In the discussion, the investigators state that NanoLuc predominantly remains attached to ApoB. This statement needs quantitative support and documentation as integrity of the fusion protein in all assays and in vivo is critical to interpretation of data.
Two existing lines of evidence previously included in the paper provide quantitative support that the light we detect is emitted from an intact ApoB-NanoLuc fusion protein. However, the Reviewer challenged us to provide some additional evidence to further support this point . In the first version of the manuscript we described experiments using native-PAGE followed by in-gel NanoLuc detection, finding that essentially all NanoLuc signal appears in the ZM, VLDL, IDL, and LDL regions of the gel. These data are consistent with NanoLuc remaining attached to ApoB-containing lipoproteins. When protease activity cleaves the bond between ApoB and NanoLuc, stereotypic degradation products are visible in the lower portion of the native gel where free proteins would migrate as shown in Supplementary Figure 6 . Secondly, density gradient ultracentrifugation showed that NanoLuc activity was essentially undetectable in the highest density fraction (Fraction 1, Figure 4b ), which corresponds to the density of free proteins (~1.35 g/mL). This indicates that the NanoLuc protein is almost exclusively associated with ApoB-containing lipoproteins. In this revised manuscript we have added an additional experiment using denaturing polyacrylamide gel electrophoresis (SDS-PAGE) to show that a specific NanoLuc antibody detects a protein migrating as a very high molecular weight entity (>250 kDa) which co-migrates with ApoB derived from human LDL, conclusively showing that NanoLuc remains fused to Apolipoprotein-B. No smaller molecular weight products were detectable, indicating that essentially all NanoLuc protein produced remains attached to ApoB. These data have been added as a new panel to Supplemental Figure 2d . Discussion of this additional experiment has been added to the main manuscript (as well as pasted below) and the protocol is described in detail in the "Western Blotting" section added to materials and methods (also pasted below).
(Results)
Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) followed by labeling with specific ApoB and NanoLuc antibodies reveal a single high molecular-weight band (>250 kDa) Supplementary Fig. 2d The Reviewer makes a good point that providing signal to noise/background ratio data and a discussion of its relevance is important and should be included in the manuscript. To address this point we have added a new panel (Supplementary Figure 7i) . Discussion of the signal to noise ratio data and method of blank subtraction was added to the quantification and statistical analysis section of the methods (pasted below).
(Methods)
One of the strengths of a chemiluminescent reporter is that it has excellent signal to background ratios. In our hands, the signal to background ratio varies significantly between assays, reaching approximately 30,000:1 in plate-based assays, 30:1 in gel-based assays, and 13:1 in microscopy assays (Supplementary Fig.  7i ). Blank subtraction was therefore not performed for the above analyses, as it was found not to have an impact on the results. This is likely due to the fact that background signal is negligible in the plate-based assays, and the remaining assays not only have very low levels of background signal, but are also quantified in terms of relative (rather than absolute) signal and thus less susceptible to skewing from the background signal.
Reviewer #1 Point 3: The authors should comment on stability of the NanoLuc signal over time in various assays as this is important for reliable quantification.
We agree with the Reviewer that the stability of NanoLuc signal over time is important for reliable quantification of the plate read data, and this information is provided in Supplementary Figure 7d showing remarkable stability of the NanoLuc signal over the course of 20 minutes across a broad concentration series. We apologize for omission of kinetic data for the electrophoresis and microscopy assays, which has now been quantified and added ( Supplementary Fig. 7e -7h ). Importantly, these data demonstrate that while the absolute intensity of NanoLuc signal does vary over time for the LipoGlo-electrophoresis and LipoGlomicroscopy techniques, the information quantified (the relative migration and localization patterns) are quite robust to moderate fluctuations in incubation time. Discussion of these findings has been added to the methods section of the manuscript (also pasted below). Fig. 7g-7h ), equilibration times below 5 minutes or greater than 20 minutes are not recommended.
(Methods) Effort should be made to ensure a consistent equilibration time between substrate addition and gel imaging. While this assay is relatively robust to small variations in incubation time (Supplementary
While the absolute intensity of NanoLuc signal will decay gradually over time 
, the distribution of NanoLuc signal is relatively robust to slight variation in incubation time. Nonetheless, it is recommended that larvae be mounted and imaged with as consistent of an incubation period as possible (ideally less than 30 minutes).

Reviewer #2:
(Remarks to the Author): This manuscript from Thierer et al., described the generation of a new knockin zebrafish in which the apoB protein is tagged with luficerase (NanoLuc). The authors showed that this novel genetically modified animal can be used to track some of metabolic features of apo-B containing lipoproteins in a spatiotemporal manner, using mtp or apoc2 loss-of-function animals or using a MTP inhibitor. Indeed, few, if there is any previous technique can track the size of apoB lipoproteins in vivo using live animals. This platform can also be used to screen compounds interfering with lipoprotein metabolism in a large scale and be adopted to other organisms. Furthermore, leveraging this novel animal model, they defined the new function of pla2g12b as a critical regulator of apoB-containing lipoprotein size. In general, this is a very interesting paper demonstrates the powerful usage of zebrafish animal model in combination with versatile gene targeting. The manuscript was well-written. While this is a well-conducted study, a few improvements may further strength their findings.
Major concerns:
Reviewer #2 Point 1: As far as we know, most lipoproteins reside in the vasculature. The in vivo luciferase signal did not show enrichment in the blood vessels ( Figure. At the onset of this project, the authors had a similar perspective to Reviewer 2 in that "most lipoproteins reside in the vasculature". However, based on our extensive review of the literature and new data provided in this paper, we believe that this perspective is biased by how lipoproteins have been traditionally studied. In general, plasma is used as the starting material for the study of lipoproteins, and thus any lipoproteins outside of the plasma are almost never examined. In this paper, we highlight an abundance of lipoproteins in several extravascular tissues including the liver, intestine, yolk-syncytial layer (YSL), central nervous system (CNS), and myosepta. While we were initially surprised by some of these observations, upon further investigation we found significant support for each of these observations in the literature. Firstly, lipoproteins are produced by the liver, intestine, and YSL, and the LipoGlo signal in these organs likely reflects both the nascent lipoproteins being secreted by these tissues, and in the case of the liver, lipoproteins being endocytosed from the circulation. Lipoproteins have also been previously detected in embryonic cerebrospinal fluid of chick embryos (see added discussion below), thus validating our detection of LipoGlo signal associated with the CNS. Lastly, individuals with mutations causing abnormally high levels of LDL (homozygous familial hypercholesterolemia) develop severe tendon defects, which is consistent with the localization of LipoGlo signal in the tendinous myosepta of larval zebrafish. Additional discussion and the relevant citations have been added to the manuscript and pasted below.
We would like to thank the reviewer for proposing a powerful experiment to validate that the observed localization pattern is not an artifact of the LipoGlo system by injecting fluorescently labelled LDL into the bloodstream. We have not only performed this experiment, but performed a related experiment using injection of DiI (a lipophilic fluorescent dye) into the larval yolk to fluorescently label endogenous zebrafish lipoproteins. The results of both of these experiments corroborate the findings of the LipoGlo-Microscopy experiment, confirming that the localization patterns observed are not an artifact of the NanoLuc tag. These findings are presented in Supplementary Fig. 5c -5e, and discussed in the main text in new sections of the methods, results, and discussion (pasted below). As a negative control, human DiI-LDL was also injected into the yolk of zebrafish larvae (Supplementary Fig. 5d) We would like to thank the reviewer for highlighting this important point. Although we perform extensive characterization of the larval lipoprotein profile using LipoGlo, since there are no alternative techniques to characterize the lipoprotein profile without the lipoGlo reporter, we cannot be certain that LipoGlo does not induce changes in the larval lipoprotein profile. To address this issue, we have performed additional experiments to characterize the lipoprotein profile of adult fish in both the wild-type and LipoGlo backgrounds using Di-I staining and native-PAGE. We found these profiles to be indistinguishable. This experiment has been added as Supplementary Fig. 8 , and corresponding sections have been added to the methods, results, and discussion (pasted below). Unfortunately we did not have a sufficient number of adult fish of the appropriate genotypes to perform these experiments in hyper/hypo-lipidemic mutants, these experiments are on-going and are beyond the scope of the current manuscript. Fig. 8 
(Results) Adult zebrafish plasma labeled with DiI confirms that LipoGlo does not disrupt the APOB-LP profile LipoGlo has revealed numerous aspects of the lipoprotein profile in zebrafish larvae, many of which are in line with our current understanding of lipoprotein homeostasis. However, as no alternative methods exist to study the lipoprotein profile in zebrafish larvae at this level of sensitivity or resolution with regard to particle size and number, it was not possible to compare the lipoprotein profile between wild-type and LipoGlo larval individuals. However, using plasma extracted from adult animals the hypothesis that LipoGlo labeling does not alter the plasma lipoprotein profile was tested. Adult zebrafish plasma lipoprotein profiles determined using native-PAGE from WT animals that were labeled with DiI were essentially indistinguishable from those homozygous for the LipoGlo reporter, although there was significant variation between individuals (likely as a result of variations in activity and feeding behavior) (Supplementary
). These data indicate that the addition of NanoLuc to the carboxy-terminal of ApoB does not disrupt the lipoprotein profile.
While no differences were apparent between wild-type and LipoGlo animals, we were able to detect a significant DiI-positive ( NanoLuc-negative) Figures 3 and 4 show differential apoB lipoprotein fractions using native gel electrophoresis and ultracentrifugation-based isolation. A verification of the presence of cholesterol using NBD cholesterol staining (or TopFLuo cholesterol-containing food feeding) and apoB using WB can further strength the conclusions.
We fully agree that the verification of the presence of ApoB or cholesterol would strengthen the support for these conclusions. Unfortunately, several technical hurdles complicate the execution of experiments. Firstly, we have not yet identified an antibody suitable for detection of ApoB in zebrafish (demonstrated in Supplementary Figure 2d) . However, the response to Reviewer # 1 point 1 (above) summarizes the additional experiments we have performed to validate that NanoLuc remains attached to ApoB, and we are unable to detect any NanoLuc that is not associated with ApoB, verifying that light emission from NanoLuc is a valid method to quantify ApoB levels.
The reviewer recommends an experiment involving top-Fluor cholesterol feeding to validate the presence of cholesterol in the native gel and density fractions. While we agree that this would be a valuable experiment in principle, we have serious concerns that this fluorescent marker would not be sufficiently sensitive to detect the lipoproteins derived from 1/10 th of an individual larva. These concerns are fueled by the observation that fluorescent reporters have significantly higher background than chemiluminescent reporters such as NanoLuc, as can be observed in Supplementary Figure 3 . Here, human LDL is saturated with the fluorescent dye DiI. When diluted to slightly over 100-fold to ~.01 mg/mL (or ~20 μM), the signal becomes nearly undetectable. By contrast, we estimate that the larval homogenate contains LDL at a concentration of approximately 1 nM, or 20,000 times below the detection limit of Di-I LDL, effectively precluding the use of fluorescent lipids to trace lipoproteins in larval homogenate. However, we were able to obtain concentrated lipoproteins from adult plasma and label them with DiI, a lipophilic dye routinely used to label lipoproteins. These results are presented as a new Supplementary Figure (Supplementary Figure 8) , and although DiI appears to label numerous additional species in zebrafish plasma (including vitellogenin), there is excellent concordance between the LipoGlo signal and DiI (as discussed above).
We would also like to direct the reviewer to a publication referenced in the manuscript (Liu, C., et al., Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia. Dis Model Mech, 2015), which pools together plasma from 40 adult zebrafish and is able to quantify the cholesterol and triglycerides in the corresponding lipoprotein fractions.
We have also validated the lipoprotein fractions in numerous other ways throughout the manuscript, for example by demonstrating that these fractions (i) respond to dietary lipid availability, (ii) respond to ApoBlowering pharmaceuticals, (iii) have the expected density of lipoproteins, (iv) show the proper size and morphology when directly visualized by electron microscopy, and (v) depend on the canonical cofactors MTP and ApoC2 for their production, turnover, and overall size distribution profile. Taken together, these observations provide a preponderance of evidence to support that these different fractions are indeed different classes/sizes of ApoB-containing lipoproteins.
Reviewer #2 Point 4: The author identified the novel pla2g12b gene in modifying lipoprotein size. What is the current study on this gene? Any association of this gene with cardiovascular disease and lipoprotein metabolism? The author may test if indeed pla2g12b deficiency augments foam cell formation in apoC2 mutant or control animals.
We share the reviewer's curiosity surrounding the Pla2g12b gene. This gene is very poorly understood, and the little data available essentially shows that this protein is catalytically inactive to phospholipid substrates, yet somehow promotes efficient triglyceride secretion via ApoB-containing lipoproteins. However, no mechanism has been proposed to explain this activity. We are very curious to see what impact this protein has on the incidence of cardiovascular disease, but no link has been reported previously. This is a particularly interesting case where abnormally small lipoproteins are produced but there is a smaller overall number of particles, which would be expected to have counteracting effects on cardiovascular disease risk and thus may explain a lack of previously published associations between this gene and cardiovascular disease. However, we believe that the detailed study of this protein (such as its mechanism of action and its impact on cardiovascular disease risk) are beyond the scope of this study. Rather, in the context of this study, the identification of Pla2g12b as a novel regulator of lipoprotein size serves as an illustrative example of the utility of the LipoGlo system in discovering new regulators of lipoprotein size, abundance, and localization. We hope that the discovery of additional genes such as this one will provide researchers with a wide array of mutations that disrupt the lipoprotein biology, all of which can be tested for their impact on cardiovascular disease risk.
Reviewer #2 Point 5 (minor): It is interesting that the animals were PFA fixed first and then the luciferase substrate was added. Is it because of high sensitivity of this NanoLuc?
PFA and Tween-20 were added to facilitate permeabilization of the zebrafish larvae. Unlike luciferin (the substrate of firefly luciferase) which freely diffuses into living cells and tissues, the NanoLuc substrate furimazine does not freely diffuse into living tissues. The remarkable stability of the NanoLuc enzyme allows it to retain its activity despite mild fixation with PFA.
Reviewer #2 Point 6 (minor): What changes in the apoB containing lipoproteins when their size become smaller and render them more atherogenic? Any in vitro or in vivo evidence?
We apologize for omission of this interesting topic. A statement and critical reference has been added to address this point (pasted below).
(Introduction)
The higher atherogenic potential of small dense LDL particles (sdLDL) has been attributed to a combination of three properties [7] , including increased rates of intimal invasion, reduced receptor-mediated clearance, and increased susceptibility to oxidation.
Reviewer #3:
(Remarks to the Author): This manuscript describes experiments to develop and validate the LipoGlo reporter for apoB containing lipoproteins in zebrafish. The authors have tagged the zebrafish homolog of apoB with a luciferase tag which allows the tracking of its lipoproteins around the transparent fish larvae. In addition, the larvae can be ground up and the lipoproteins analyzed by electrophoretic techniques to determine general distributions between CM, VLDL, IDL and LDL. The authors used the system to identify potentially new sites of apoB-LP association within the larval body and, as a proof of concept, identified a gene that likely affects apoB-LP metabolism in fish. Overall, this is an interesting system. The resolution of the system, both in terms of the gel electrophoresis size analysis and the whole body localization studies, is perhaps a bit disappointing. I was hoping that it might be possible to see associations that are more related to atherosclerosis development like accumulation of apoB-LPs in the vasculature, for example. However, it clearly has potential uses in screening for genes and drug treatments that affect apoB-LP metabolism. However, there were some deficiencies in the characterization of the system and inconsistencies in the data that reduced enthusiasm for this work in its current state. My specific comments are outlined below.
Reviewer #3 Point 1: The abbreviation ABCLs seems a bit clunky for apoB containing lipoproteins. The authors should consider using a more intuitive abbreviation like apoB-LPs or something similar. It is only a little longer, but much clearer.
The authors were also frustrated by the imprecise and inconsistent terminology used to discuss ApoBcontaining lipoproteins in the existing literature. At the Reviewer's recommendation, we have adopted the suggested acronym ApoB-LPs and incorporated it throughout the manuscript.
Reviewer #3 Point 2: The conclusion that the LipoGlo signal does not disrupt normal production, secretion and turnover of lipoproteins appears based on the observation that the homozygous fish are healthy, fertile with no abnormal or morphological phenotypes. This seems like light evidence. One would expect to see some sort of size pattern analysis between WT and homozygous fish to show that they are similar. Also, a demonstration that the modified LPs can interact with the LDL receptor to a similar extent as WT would also be in order. I realize that it is difficult to get enough material for these types of validations from fish. But these days it should be relatively straightforward to produce this same tag in a mouse system where the consequences of the tag attachment can be very easily studied and compared to non-labeled (i.e. LDL-R binding, size pattern, etc). As it stands, I am not convinced by the data presented that the tag is completely benign for apoB function.
We agree with the reviewer that the lack of an overt morphological phenotype would constitute very light evidence that lipoprotein homeostasis is not disrupted. However, throughout the paper we have assembled numerous lines of evidence to validate that various aspects of lipoprotein homeostasis are preserved in LipoGlo animals. For example, the fasting and feeding experiments demonstrate that lipoprotein production is lipid-dependent, and fasting leads to lipoprotein uptake and turnover. Studies in mutant lines show that lipoprotein production is MTP dependent, and that particle turnover is ApoC2 dependent, thus validating that interaction with these central lipoprotein processing genes is intact in LipoGlo larvae. While interaction with the LDL-receptor is not tested directly, the drop in total NanoLuc signal and clearance from peripheral tissues as wild-type larvae are fasted implies that receptor mediated endocytosis is taking place. Biochemical experiments show that the particles are the appropriate size and density, and have the appropriate morphology on electron micrographs.
We concede that despite all the above evidence, a critical experiment is missing. Given that it is not possible to characterize the larval lipoprotein profile without using LipoGlo, we were unable to compare the lipoprotein profiles between wild-type and LipoGlo larvae. The reviewer suggests recreating the LipoGlo reporter in mouse, which we believe is an exciting future direction but is beyond the scope of this study. As an alternative, we have compared the adult plasma lipoprotein profiles between wild-type and LipoGlo fish, as described above in the response to Reviewer #2 point 2. This experiment (added as Supplementary Figure 8) shows that the adult plasma profile is indistinguishable between wild-type and LipoGlo animals.
We have also added another experiment to strengthen this conclusion, which was also performed in response to Reviewer #2 point 1. We found that when DiI is used to label endogenous zebrafish lipoproteins (without the NanoLuc tag), the same localization patterns are observed when we compare to the results of the LipoGlo microscopy experiments. This provides further support that lipoproteins tagged with NanoLuc does not disrupt production, secretion, or turnover of lipoproteins. These topics are discussed throughout the manuscript as outlined in the responses to Reviewer #2 points 1 and 2.
Reviewer #3 Point 3: The method uses crude larval homogenates. Presumably, this captures those lipoproteins in plasma. However, with cellular disruption that is also undoubtedly occurring, how can the authors distinguish between mature plasma particles and those intracellular particles still undergoing synthesis?
The reviewer is correct in noting that this method uses crude homogenates, and thus includes nascent intracellular lipoproteins that would not be included in a typical analysis of plasma lipoproteins. While we cannot conclusively distinguish between particles in the plasma versus those undergoing synthesis, we have made several observations that help to address this point.
Our working hypothesis is that nascent lipoproteins are still contained within or associated with components of the secretory pathway, including the ER and pre-VLDL transport vesicles, which greatly retards their mobility. We thus suspect that all intracellular ApoB is present within the zero-mobility (ZM) band. This is evidenced by the fact that small lipoproteins are essentially undetectable in ApoC2 mutants (Figure 3c ). If nascent lipoproteins that had not yet been fully lipidated and secreted were able to migrate into the gel, we would be able to detect these small lipoproteins migrating far into the gel, but no such particles are observed and thus are presumably retained in the ZM band. As further support for this model, in 6 dpf mtp -/-mutant larvae, essentially all lipoproteins are present in the lipoprotein-producing tissues (liver and intestine, Figure  5d ). Correspondingly, essentially all signal on the native gel is restricted to the ZM band. Thus, while there is ambiguity within the ZM band (relevant section pasted below), we are confident that lipoproteins migrating into the gel are indeed plasma lipoproteins.
(Results)
ApoB-LPs that remain within the loading well are classified as the "zero mobility" (ZM) fraction, which should include chylomicrons [37], remnants, aggregates [38] , and intracellular ApoB complexed with components of the secretory pathway (such as the ER, golgi, and other secretory vesicles) [39] .
Reviewer #3 Point 4: The size analyses of the homogenates seem problematic. The authors used a Di-I labeled (presumably human) LDL as a standard in the analysis. However, the migration of this standard in Fig. 3a clearly falls between IDL and VLDL in the size profile laid out in Fig. 3b . For example, the standard runs just below the particles classified as "VLDL" in the apoC2 KO homogenates. The authors state that the Di-I stain reduces the mobility of the standard (data not shown). So why use this as a standard? It would seem much more rigorous to introduce this same tag into mouse apoB 100 (as suggested above) and use mouse plasma lipoproteins (identically tagged) as a proper and much more comprehensive reference.
Our goal for developing an appropriate migration standard was to increase reproducibility and ensure consistent results between labs. We believe that Human DiI-LDL is the ideal solution to achieve these goals, primarily because it is commercially available. This enables labs around the world to access a consistent product that meets industry-level quality control, provides customer support, can be purchased and shipped rapidly, and can meet essentially any level of demand. While we are enthusiastic to recreate the LipoGlo reporter in a mouse system and those efforts are beginning in the Farber lab and with collaborators, it is outside of the scope of the present study. Also, the use of NanoLuc-labelled mouse LDL as a normalization standard would shift the burden of production, quality control, billing, and shipping of this essential resource onto an academic entity with limited resources that would inevitably be less efficient, smaller-scale, and less reproducible than ThermoFisher Scientific (the current supplier). Supplementary Figure 3 provides detailed explanation of the utility of DiI LDL as a normalization standard, showing that it greatly reduces variability between runs despite the fact that it does not migrate at the same rate as NanoLuc-labeled zebrafish LDL. Supplementary panel 3g has also been added, which shows a dose-response between concentration of DiI and changes in electrophoretic mobility.
Although human DiI-LDL migrates more slowly than NanoLuc-labeled LDL, which is at least partially attributable to migration retardation by DiI (Supplementary Fig. 3g) , this band provides a highly reproducible standard for registration and normalization across gels (Supplementary Fig. 3 ).
Reviewer #3 Point 5: The subclass abundance plots do not make sense in Fig. 3F . Take the first panel, WT. The plot suggests that the levels of VLDL at day 3 are lower than they are at day 5. This is inconsistent with the gel image in panel C. Another example is apparent in the apoC2-/-plot. The graph suggests that VLDL levels in days 3 and 4 are on par with days 5 and 6. However, they are clearly reduced in day 5 and 6 in the gel image.
We apologize for the confusion, and in light of the Reviewer's concerns have clarified the labelling and discussion of these plots in the main text, the labels of the Figures themselves, as well as the Figure legends. To specifically address the reviewers first example, the level of VLDL across WT development is represented by the second-lightest shade of gray in Fig. 3F (note a label was added to this panel for improved clarity). On these 100% stacked line graphs, the thickness of that shade of gray at that time point reflects the relative abundance of that species. Note that, consistent with the gel image, this species is substantially more abundant at day 3 than day 5 (this shade of gray gradually gets thinner from 2-6 dpf). These data are presented in a different way in Supplemental Fig. 4 for added clarity.
To specifically address the reviewers second example, the key distinction is that these plots represent relative abundance rather than total/absolute abundance. Indeed, there is a clear peak in signal intensity at days 3 and 4 of development, and this is fully consistent with the measurements of the total abundance of particles reported in Figure 2c (plate-reader measurements). However, even though there are changes in the total number of particles, the relative abundance of each particle class remains remarkably consistent in the ApoC2 mutant throughout development, with approximately 40% of the total LipoGlo signal in the VLDL band and 50% of the signal in the ZM band. This conclusion is also displayed in Supplemental Figure 4 .
The relevant modifications to the main text are pasted below. (Fig. 3f-h ).
(Figure legend)
Note that relative abundance was quantified, so the sum of all species will always equal 100% despite changes in total abundance over time Reviewer #3 Point 6: Some figure references in the text are incorrect. Example, line 293.
We thank the reviewer for calling attention to this error, and have made the appropriate corrections.
Reviewer #3 Point 7: The authors have not directly shown that the NanoLuc label always remains associated with the lipoprotein. This is mentioned in the discussion, but it is important. If there were significant cleavage of the tag occurring then the resulting data would no longer reflect the apoB-LP. Again, validation studies in the mouse, where there is enough plasma to actually track the lipoproteins themselves, would seem to be a needed step in the validation of this system. We agree that this is a critically important point, and has been addressed with additional experiments and discussion as described above. See response to Reviewer #1 point 1.
Reviewer #3 Point 8: The identification of pla2g12b is interesting and does suggest a high throughput utility for the system. However, I was surprised that if several mutant lines from the zebrafish mutation project that "had predicted mutations in genes involved in lipid metabolic pathways" were indeed studied, why was there only 1 hit? What were the other putative knock outs/mutations tested? Have those been shown to affect apoB-LPs in mice or humans? If so, why were they missed in the zebrafish? This information would go directly to the sensitivity of this assay in a high throughput setting.
We apologize for the confusion, and have clarified the discussion in the main text. Briefly, the Farber lab has a longstanding relationship with the Sanger zebrafish mutation project and history of using a variety of assays to evaluate mutants from this collection for defects in lipid metabolism. However, a detailed investigation of transcript processing in several ENU alleles revealed that many of the alleles we were initially interested in testing underwent alternative splicing to compensate for their predicted mutations. Following this analysis, Pla2g12b and abca1b were the only alleles with altered transcript levels, and were thus selected as ideal candidates for breeding into the LipoGlo background. A reference was added that reports the results of the mRNA analyses (Anderson, J.L., et al., mRNA processing in mutant zebrafish lines generated by chemical and CRISPR-mediated mutagenesis produces unexpected transcripts that escape nonsense-mediated decay. PLoS Genet, 2017.), and the main text was modified as outlined below.
In an effort to identify novel regulators of the ApoB-LP profile using the LipoGlo system, we analyzed a collection of mutants from the zebrafish mutation project [43] that had predicted mutations in genes involved in lipid metabolic pathways. Of the six ENU alleles studied, two alleles (abca1b and pla2g12b) were particularly promising as we detected nonsense-mediated decay in the mutant transcripts [44] . Studies of abca1b using LipoGlo are underway, but we have discovered that larvae homozygous for an essential splice site mutation (sa659) in phospholipase A2 Group XII B (pla2g12b) showed perturbations in their ApoB-LP profile (Fig. 6) .
